Skip to content

MIPS/CQM Archive

2024 MIPS Measure #259: Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)

2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) ‌MEASURE TYPE: Outcome – High Priority Description Percent of patients undergoing endovascular repair of small orContinue reading “2024 MIPS Measure #259: Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)”

2024 MIPS Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)

2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) ‌MEASURE TYPE: Outcome – High Priority Description Percent of asymptomatic patients undergoing Carotid Endarterectomy (CEA) whoContinue reading “2024 MIPS Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2)”

2024 MIPS Measure #118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF <= 40%)

2024 COLLECTION TYPE: MIPS Clinical Quality Measures (CQMS) ‌MEASURE TYPE: Process ‌Description ‌Percentage of patients aged 18 years and older with a diagnosis ofContinue reading “2024 MIPS Measure #118: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy – Diabetes or Left Ventricular Systolic Dysfunction (LVEF <= 40%)"